黄腐酚对克罗恩病成人的微生物组与特征研究(XMaS试验):一项II期三盲安慰剂对照临床试验方案
本研究为II期三盲随机安慰剂对照试验方案,拟纳入临床活动期克罗恩病成人(n≤32),随机接受每日24 mg黄腐酚胶囊或安慰剂并随访8周,评估安全性、耐受性、炎症生物标志物、血小板功能、疾病活动度、粪便微生物组成及黄腐酚代谢,并与既往I期健康成人试验结果比较。
要点
- 黄腐酚每日24 mg用于临床活动期克罗恩病成人,主要评估安全性与耐受性。
- 每2周评估不良事件、炎症标志物、血小板功能、疾病活动指数及微生物组成。
- 试验结果将与既往I期健康成人试验中黄腐酚的作用进行比较。
核心结论
- 该II期试验将评估每日24 mg黄腐酚在临床活动期克罗恩病成人中的安全性与耐受性,并评估其对炎症生物标志物、血小板功能、临床活动度、粪便微生物组成及代谢的影响。
研究设计与样本
- 三盲、随机、安慰剂对照II期临床试验,纳入临床活动期克罗恩病成人,样本量n≤32,随机接受每日24 mg黄腐酚胶囊或安慰剂,随访8周。
主要发现
- 方案计划每2周查询不良事件,并评估临床安全性生物标志物、血液和粪便炎症标志物、血小板功能、克罗恩病活动指数评分、粪便微生物组成及血、尿、粪中黄腐酚代谢物谱。
- 本试验中黄腐酚对炎症生物标志物、血小板功能、微生物群及多组学标志物的效应,将与既往I期健康成人试验中黄腐酚的效应进行比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xanthohumol (XN), a bioactive flavonoid from Humulus lupulus with anti-inflammatory properties, has potential benefits for patients with Crohn's disease (CD), a type of inflammatory bowel disease. We recently completed and published results of a placebo-controlled phase I clinical trial demonstrating the safety and tolerability of 24 mg XN daily for 8 weeks. The present study aims to evaluate the safety and tolerability of the same dose of XN adults with clinically active CD in a placebo-controlled phase II clinical trial. Additional aims will assess the impact of XN on inflammatory biomarkers, platelet function, CD clinical activity, and stool microbial composition. The metabolism of XN will also be evaluated. This article provides a model protocol for consideration in investigations of XN or other natural products in disease states. METHODS: A triple-masked, randomized, placebo-controlled trial will be conducted in adults with clinically active CD. Participants (n ≤ 32) will be randomized to either 24 mg encapsulated XN per day or placebo and followed for 8 weeks. Throughout the trial, participants will be queried for adverse events. Biomarkers of clinical safety, blood and stool markers of inflammation, platelet function, Crohn's Disease Activity Index score, stool microbial composition, and XN metabolite profiles in blood, urine, and stool will be assessed every 2 weeks. DISCUSSION: We describe the protocol for a phase II clinical trial that evaluates the safety and tolerability of XN in adults with active CD, as well as evaluate metabolism and mechanisms that are relevant to CD and other diseases with underlying inflammation and/or gut permeability. The effects of XN on inflammatory biomarkers, platelet function, the microbiota, and multi-omics biomarkers measured in this phase II trial of adults with CD will be compared to the effects of XN in healthy adults in our previous phase I trial. The results of the study will advance the evidence guiding the use of XN in patients with CD. TRIAL REGISTRATION: ClinialTrials.gov NCT04590508. Registered on October 19, 2020.
引用
- Langley BO, Ryan JJ, Phipps J, et al. Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial. Trials. 2022. PMID: 36273173. doi:10.1186/s13063-022-06782-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。